Attachment Insecurity and Depression, Anxiety in Ovarian Cancer Patient Partner-Caregivers
A cross-sectional study sought to determine how caregiving responsibilities affect mental health of partner-caregivers.
Ovarian Cancer
Avelumab Provides No Benefit as Frontline Therapy or Maintenance in Ovarian Cancer
Avelumab did not improve progression-free survival when given concurrently with chemotherapy or as maintenance.
Updated Data Confirm Safety of Olaparib Maintenance in Advanced Ovarian Cancer
Most adverse events in the olaparib arm were manageable with supportive treatment or dose modifications.
Use of PARP Inhibitor Maintenance on the Rise in Platinum-Sensitive, Recurrent Ovarian Cancer
PARP inhibitor use increased regardless of BRCA mutation status.
Avelumab Doesn’t Improve Survival in Platinum-Refractory Ovarian Cancer
There was no improvement in progression-free or overall survival.
Benefit of Niraparib Maintenance May Extend Beyond First Progression in Ovarian Cancer
There was an improvement in second progression-free survival, but not overall survival, with niraparib.
Rucaparib Bests Standard of Care in BRCA-Mutated, Relapsed Ovarian Cancer
Rucaparib prolonged progression-free survival.
Atezolizumab Does Not Prolong Progression-Free Survival in Newly Diagnosed, Advanced Ovarian Cancer
There was no benefit with atezolizumab, regardless of PD-L1 status.
Secondary Cytoreduction Improves Progression-Free Survival in Platinum-Sensitive, Relapsed Ovarian Cancer
The median progression-free survival was nearly 6 months longer in patients who underwent surgery.
Lack of Standardized Screening Linked to Increased Incidence of Many HPV-Related Cancers
For HPV-related cancers without standardized screening, incidence rates increased between 2001 and 2017.
- Loading...
Loading...
Next post in Gynecologic Cancer
Loading... 
Loading...